Department of Basic, Preventive and Clinical Sciences, Transilvania University, 500036 Brasov, Romania.
Faculty of Product Design and Environment, Transilvania University, 500036 Brasov, Romania.
Medicina (Kaunas). 2024 Oct 27;60(11):1761. doi: 10.3390/medicina60111761.
Diabetes medications can affect weight and cardiovascular health. Some medications can aid in weight management, while others may lead to weight gain. Patients must be monitored and receive appropriate care to manage weight and prevent cardiovascular complications. Despite advancements in diabetes treatments that can influence weight and cardiovascular outcomes, ongoing research is necessary in this intricate field. Long-term effects, individual variations, and combination therapies are still subjects of uncertainty and ongoing investigation. The major objective of the research is to evaluate the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on body weight in diabetic patients through a scientometric assessment. Methodology: Research data were gathered from the Web of Science Core Collection (WoSCC) database by searching for the keywords "Body Weight", dulaglutide, and semaglutide, identifying 60 relevant articles in the field. While there are advantages in managing diseases in which the cardiovascular system is implicated, there are also clinical considerations for personalized medicine and shared decision-making. The scientometric analysis of the articles revealed important insights into how dulaglutide and semaglutide impact weight management and their potential benefits for managing cardiovascular diseases in individuals with diabetes. Conclusions: Semaglutide shows superior outcomes compared to other commercially available GLP-1RAs, particularly in improving blood sugar control, lowering body weight, and addressing other cardio-metabolic risk factors in individuals with type 2 diabetes (T2DM). The findings suggest that GLP-1 RAs have the potential to provide cardiovascular protection by influencing various physiological factors such as blood pressure, pulse rate, glycated hemoglobin (HbA1c) levels, and the urinary albumin-to-creatinine ratio (RAC). The development and validation of the 4GI model provides a sophisticated tool for evaluating the complex interactions involved in diabetes treatments, offering insights into the mechanisms of action of various medications.
糖尿病药物会影响体重和心血管健康。一些药物可以帮助控制体重，而另一些药物则可能导致体重增加。患者必须接受监测并接受适当的护理，以管理体重并预防心血管并发症。尽管糖尿病治疗方面的进展可以影响体重和心血管结局，但在这个复杂的领域仍需要进行持续的研究。长期影响、个体差异和联合治疗仍然是不确定和正在研究的主题。该研究的主要目的是通过科学计量评估评估胰高血糖素样肽-1 受体激动剂（GLP-1 RAs）对糖尿病患者体重的影响。方法：通过在 Web of Science Core Collection（WoSCC）数据库中搜索“体重”、度拉糖肽和司美格鲁肽等关键词，收集研究数据，共确定了该领域的 60 篇相关文章。尽管在涉及心血管系统的疾病的管理方面有优势，但在个性化医学和共同决策方面也存在临床考虑因素。对文章的科学计量分析揭示了有关度拉糖肽和司美格鲁肽对体重管理的影响及其在糖尿病患者中管理心血管疾病的潜在益处的重要见解。结论：与其他市售 GLP-1RA 相比，司美格鲁肽显示出更好的结果，特别是在改善血糖控制、降低体重和解决 2 型糖尿病（T2DM）患者的其他心血管代谢风险因素方面。研究结果表明，GLP-1RAs 通过影响血压、脉搏率、糖化血红蛋白（HbA1c）水平和尿白蛋白与肌酐比（RAC）等各种生理因素，有可能提供心血管保护。4GI 模型的开发和验证为评估糖尿病治疗中涉及的复杂相互作用提供了一种复杂的工具，深入了解各种药物的作用机制。
